SanBio Co Ltd (4592.T)

4592.T on Tokyo Stock Exchange

16 Mar 2018
Change (% chg)

¥-255 (-6.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

SanBio signs commitment line contract worth 500 mln yen
Tuesday, 31 Oct 2017 

Oct 31(Reuters) - SanBio Co Ltd <4592.T>:Says it signed a commitment line contract worth 500 million yen, with Mitsubishi UFJ Trust and Banking Corporation, on Oct. 31.Commitment period from Oct. 31 to July 31, 2020 .  Full Article

SanBio says first patient randomizes in STEMTRA trial for traumatic brain injury
Monday, 11 Jul 2016 

SanBio Co Ltd <4592.T>: Says SanBio Inc., a subsidiary of SanBio Co., Ltd says the randomization of the first patient in the STEMTRA Phase 2 clinical trial study for traumatic brain injury . Says the trial is enrolling patients in both the United States and Japan, and the first patient was randomized at Emory University Hospital in Atlanta, GA .Says the STEMTRA “Stem cell therapy for traumatic brain injury” trial will examine the effects of SB623 stem cell treatment in patients with chronic motor deficits resulting from traumatic brain injury.  Full Article

SanBio announces clinical trial involving regenerative cell treatment for patients with traumatic brain injury permitted in Japan
Wednesday, 6 Apr 2016 

SanBio Co Ltd:Says it to conduct clinical trial for chronic traumatic brain injury with allogeneic stem cells in Japan.Says the 30-day review period of Clinical Trial Notification of the regenerative cell therapy SB623 for traumatic brain injury in Japan, which was submitted to Pharmaceuticals and Medical Devices Agency (PMDA) as of March 7, has passed without further concern.  Full Article

SanBio signs term loan contract with commitment line
Thursday, 31 Mar 2016 

SanBio Co Ltd:Signed a term loan contract with commitment line worth 1 bln yen on March 31 with commitment period from April 1, 2016 to March 31, 2025.  Full Article

BRIEF-SanBio and Teijin to terminate licensing agreement regarding SB623 for stroke treatment

* Says co and Teijin Limited would terminate the exclusive licensing agreement signed in 2009, regarding the development and marketing of SB623 for stroke treatment in Japan